Item 1.01 Entry into a Material Definitive Agreement.

On October 1, 2012, ViroPharma Biologics, Inc., a wholly owned subsidiary of ViroPharma Incorporated, ("ViroPharma Biologics") entered into an amendment (the "Amendment") to its Agreement for the Purchase and Sale of Blood Plasma (the "Agreement") with DCI Management Group LLC ("DCI"). Pursuant to the Amendment the parties agreed to increase the base purchase price per liter of plasma, increase the minimum purchase requirements, adjust the base price in the event certain testing is performed by certain third parties, and modified the price adjustment terms for future periods. ViroPharma Biologics needs an adequate supply of plasma in order to manufacture Cinryze. The purchase commitment for 2012 is approximately $37 million, which includes purchases made during 2012 under the Agreement, and the purchase commitment for 2013 is also approximately $37 million. Beginning in 2014, the annual purchase commitment will range between approximately $33 million and $37 million, subject to annual adjustments to the purchase price based on market conditions. In addition, the Amendment allows DCI to use an additional testing laboratory. The previously disclosed material terms of the Agreement remain unchanged and in effect. ViroPharma Incorporated intends to file a copy of the foregoing agreement as an exhibit to the Company's quarterly report on Form 10-Q for the fourth quarter of 2012.

---